1Bracke M, Lammers JW, Coffer PJ, et al. Cytokine-induced inside-out activation of FcalphaR(CD89) is mediated by a single serine residue(S263) in the intracellular domain of the receptor. Blood, 2001,97(11):3478-3483.
2Marone M, Scambia G, Bonanno G, et al. Transforming growth factor-beta 1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects. Leukemia,2002,16(1):94-105.
3van Zandbergen G,van Kooten C,Mohamad NK,et al.Reduced binding of immunoglobulin A(IgA)from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor,CD89.Nephrol Dial Transplant,1998,13(12):3058-3064.
4Narita I, Goto S, Saito N, et al.Genetic polymorphisms in the promoter and 5' UTR region of the Fc alpha receptor(CD89) are not associated with a risk of IgA nephropathy. J Hum Genet, 2001,46(12):694-698.
5Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, et al. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol, 2001,167(5):2861-2868.
6Leung JC, Tang SC, Lam MF, et al. Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy. Kidney Int, 2001,59(1):277-285.
7Johansen FE, Braathen R, Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand J Immunol, 2000,52(3):240-281.
8Endo M, Ohi H, Satomura A, et al. Regulation of in situ complement activation via the lectin pathway in patients with IgA nephropathy. Clin Nephrol, 2001,55(3):185-191.
9Pirulli D, Boniotto M, Vatta L, et al. Polymorphisms in the promoter region and at codon 54 of the MBL2 gene are not associated with IgA nephropathy. Nephrol Dial Transplant, 2001,6(4):759-764.
10Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-beta signal transduction. J Cell Sci,2001,114(Pt 24):4359-4369.
5Sano T, Hiki Y, Kokubo T, et al. Enzymatically deglycosylated human lgA1 molecules accumulate and induce inflammatory cell reaction in rat glomeruli[ J]. Nephrol Dial Transplant ,2002,17 ( 1 ) :50 - 56.
6Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy[ J]. Serain Nephrol,2004,24 ( 3 ) : 197 - 217.
7Levy M, Gonzalez- Burchard G,Broyer M,et al. Berger's, disease in children. Natural history and outcome [ J ]. Medicine ( Baltimore), 1985, 64(3) :157 - 180.
8Yoshikawa N,Ito H,Sakai T,et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy[ J]. J Am Soc Nephrol.1999,10( 1 ) :101 - 109.
9Yoshikawa N, Nakanishi K, Ishikura K,et al. Combination therapy with 'mizoribine for severe childhood IgA nephropathy:A pilot study [ J ]. Pediatr Nephrol,2008,23 ( 5 ) :757 - 763.
10Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephmpathy[ J ]. Semin Nephrol,2004,24 ( 3 ) :256 - 268.
